Telix H1 2026 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026. An investor webcast and conference call will be held at 9:00 a.m....
Kuching to Host Asia’s Leading Diabetes Experts at “Diabetes Asia 2026” Conference (DAC 2026)
KUCHING, Malaysia, July 30, 2026 /PRNewswire/ -- As diabetes continues to place an increasing burden on Malaysia's healthcare system — affecting an estimated 4.75 million Malaysian adults - Kuching will become the regional meeting point for leading diabetes experts this October as it hosts the "Diabetes Asia 2026" Conference (DAC 2026). The conference will bring together internationally renowned...
AiRISTA Receives Frost & Sullivan’s 2026 North American Competitive Strategy Leadership Recognition for Healthcare Real-Time Location Solutions
The company's interoperable RTLS platform, customer-centric strategy, and continuous innovation are transforming healthcare asset management and operational efficiency. SAN ANTONIO, July 30, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that AiRISTA has received the 2026 North American Competitive Strategy Leadership Recognition in the healthcare asset management solutions industry for its outstanding achievements in competitive strategy, innovation, and...
HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates
HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has established HKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration Program. The program supports AI drug-discovery teams in translating AI-generated targets, molecules and mechanism hypotheses into in vivo pharmacology, mechanism,...
Insilico Medicine Launches the Industry’s First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- As general-purpose and domain-specific AI models rapidly infiltrate drug discovery, one critical question looms over the pharmaceutical sector: Can these models...
NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States
New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis to United States healthcare providers. OSAKA, Japan, July 30, 2026 /PRNewswire/ -- NIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food and Drug Administration (FDA), effective July 28, 2026. The clearance enables the introduction of HDs (Hemodialysis...
Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors
Business development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla., July 30, 2026 /PRNewswire/ -- Continuity Biosciences today announced the appointment of Vicky Papoutsis to its Board of Directors. Vicky brings more than 25 years of biopharmaceutical business development and corporate strategy...
Ping An Group Upgrades Longevity Management Service System, Unveils 11 Health Longevity Centers Nationwide
SHANGHAI, July 30, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An Group") held a service upgrade press conference yesterday themed "Professionalism Safeguards a Century of Wellbeing", officially upgrading its "Ping An Health Longevity Management Service System". Relying on three core capabilities—medicine, AI, and cutting-edge technology—and through systematic risk prevention and proactive intervention, the system...
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
CHENGDU, China, July 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) has been accepted for review by the Center for...
As the Silver Economy Embraces AI: China’s Elderly Care Innovation Competition Reveals Three Trends
SHANGHAI, July 30, 2026 /PRNewswire/ -- In Shanghai, China's city with the deepest aging population, a national competition focused on silver economy innovation has just concluded. The AID Silver Economy Creativity, Innovation and Entrepreneurship Competition, held by Shanghai Aging Industry Development Co., Ltd., drew 753 entries from 19 provinces, with 26 projects winning awards. The winning solutions offer...
